SOCIUM

About:

SOCIUM is an AI-powered drug discovery and development company focused on first-in-class small molecules.

Twitter/X: socium_inc

Top Investors: UTEC - The University of Tokyo Edge Capital Partners

Description:

SOCIUM is an AI-powered drug discovery and development company focused on first-in-class small molecules. The company currently has a development portfolio of over 23 diseases, including oncology and rare diseases. The company replaces multiple steps in the traditional drug discovery process with an in-silico system using our cutting edge algorithm, established a system to identify the drug discovery target in a few months. By taking a systems biology approach using our Augmented intelligence and Machine Learning – instead of hypothesizing the mechanism of a disease and focusing on only a few related compounds, we profile the entire disease by analyzing various OMICS data.

Total Funding Amount:

260M JPY

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Tokyo, Tokyo, Japan

Founded Date:

2017-09-01

Contact Email:

contact(AT)socium.co.jp

Founders:

Katsuhisa Horimoto, Manabu Takahashi

Number of Employees:

11-50

Last Funding Date:

2018-10-12

IPO Status:

Private

Industries: